NRX Pharmaceuticals, Inc. current report, 24 May 2021

Full document

NRX Pharmaceuticals, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K, dated May 24, 2021, details the completion of a business combination between Big Rock Partners Acquisition Corp. (BRPA) and NeuroRx, Inc. Following the merger, the combined entity operates as NRX Pharmaceuticals, Inc. (NRX), a holding company whose primary asset is equity in NeuroRx. The company ceased to be a shell company upon closing. Common stock and warrants began trading on the Nasdaq Global Market under the symbols "NRXP" and "NRXPW" on May 25, 2021.

Key Financial Metrics and Capital Structure

The filing does not provide specific revenue, profit, or cash flow figures for the combined entity within this text, as historical financial data is incorporated by reference from the Proxy Statement/Prospectus. However, the following capital structure and transaction metrics are disclosed:

  • PIPE Investment: The company consummated a Private Investment in Public Equity (PIPE) transaction raising $10,000,000 through the sale of 1,000,000 shares of Common Stock at $10.00 per share.
  • Outstanding Shares: Following the transaction, there are 47,459,958 shares of Common Stock issued and outstanding.
  • Trust Account: Public shareholders had the right to redeem shares for a pro rata portion of the trust account, which held approximately $6.0 million (approximately $10.80 per share) as of April 23, 2021.
  • Contingent Consideration: NeuroRx securityholders received the right to earn up to 25,000,000 Earnout Shares and $100,000,000 in Earnout Cash based on specific FDA regulatory milestones for the COVID-19 drug (ZYESAMI) and the Antidepressant Drug Regimen (NRX-100/101) by December 31, 2022.
  • Employees: As of May 28, 2021, the company employed approximately 32 persons worldwide.

Material Changes and Corporate Actions

The primary material change is the completion of the merger, resulting in a change of control and corporate identity. Key actions include:

  • Management Changes: Jonathan C. Javitt was appointed Chief Executive Officer, Chairman, and Director. William Fricker was appointed Chief Financial Officer. Previous BRPA officers resigned.
  • Board Composition: The Board was reconstituted with six directors, including Jonathan Javitt, Sherry A. Glied, Patrick J. Flynn, Daniel Troy, Aaron Gorovitz, and Chaim Hurvitz. Lt. General H.R. McMaster was appointed as an independent director on May 26, 2021.
  • Accountant Change: The company replaced Marcum LLP with KPMG LLP as its independent registered public accounting firm for the 2021 audit.
  • Stockholder Agreements: Certain stockholders entered into a Lock-Up Agreement restricting share transfers for six months or until the stock price exceeds $12.00 per share for 20 trading days. A Registration Rights Agreement was executed with the Javitt Stockholders.

Outlook, Risks, and Contingencies

Management's outlook is heavily dependent on regulatory approvals for its pipeline products. The filing highlights significant risks and contingencies:

  • Regulatory Milestones: Future value is contingent on the FDA granting Emergency Use Authorization (EUA) and filing a New Drug Application (NDA) for ZYESAMI, and FDA approval for the NRX-100/101 regimen by December 31, 2022.
  • Forward-Looking Statements: The company cautions that actual results may differ materially due to risks including limited operating history, competition, general economic factors, and the impact of the COVID-19 pandemic.
  • Legal Proceedings: The company is subject to legal proceedings in the ordinary course of business but does not expect them to have a material adverse effect.
  • Dividends: The company has no current plans to pay cash dividends and intends to retain earnings for operations and expansion.

Investor Verification Checklist

  • Verify the status of the 25,000,000 Earnout Shares and $100 million Earnout Cash milestones regarding FDA approvals for ZYESAMI and NRX-100/101.
  • Review the Proxy Statement/Prospectus for detailed historical financial data of NeuroRx and pro forma financial information, as this 8-K incorporates such data by reference.
  • Confirm the Lock-Up Agreement expiration dates and price triggers ($12.00 per share) for major shareholders to assess potential near-term selling pressure.
  • Monitor the trust account redemption deadline (June 8, 2021) and the final number of shares remaining after public shareholder redemptions.
  • Assess the impact of the change in auditors from Marcum LLP to KPMG LLP on future financial reporting.